<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00838864</url>
  </required_header>
  <id_info>
    <org_study_id>FEMH-97-C-010</org_study_id>
    <nct_id>NCT00838864</nct_id>
  </id_info>
  <brief_title>Comparison of 3 Days and 7 Days Intravenous Ceftriaxone Prophylaxis for Variceal Bleeding</brief_title>
  <official_title>Comparison of 3 Days and 7 Days Intravenous Ceftriaxone Prophylaxis in Patients With Acute Variceal Bleeding</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Far Eastern Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Far Eastern Memorial Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prophylactic antibiotics have been routinely recommended for cirrhotic patients with upper
      gastrointestinal bleeding recently. However, the regimen and duration of its use remain an
      inconclusive issue. Quinolones and 3rd generation cephalosporins have been more often used
      for prophyalxis recently. The duration for antibiotic usage were variable in the literatures,
      ranged from 4-10 days. The latest guideline from AASLD in 2007 was 7 days. In the survey of
      infections in cirrhotic patients with UGI bleeding performed by Bernard et al, most
      infections occurred in the first 5 days and half within the first 48 hours. Therefore,
      considering the cost-effectiveness and drug resistance issues, the necessity for such
      prophylaxis for 7 days may need to be re-evaluated.

      The purpose of our study is to investigate the antibiotic prophylaxis duration for cirrhotic
      patients with acute gastro-esophageal variceal bleeding. We will enroll those patients
      suffering from variceal bleeding documented by endoscopic examination and without apparent
      evidence of infection. Those who have received antibiotics within 2 weeks, are less than 18
      years old, get pregnant, have malignancy other than HCC, have allergy to ceftrioxone are
      excluded. After receiving well explanation and giving consent, these patients are randomly
      allocated to 2 groups and receive prophylactic antibiotic just after endoscopic examination;
      Group I: receiving ceftriaxone 500 mg iv bolus stat and then q12h for 3 days, Group II:
      receiving ceftriaxone 500 mg iv bolus stat and then q12h for 7 days. They will receive
      appropriate endoscopic treatment for gastro-esophgeal varices and glypressin 1mg q6h for 3
      days. They will start to feed on the 2nd day if not contraindicated. The 2nd endoscopic
      treatment for varices will be performed 2 weeks later. We record the demographic data, vital
      signs, transfusion amount; check hemogram, U/A, CXR, ascites routine (with apparent ascites),
      classification of variceal size and Child-Pugh classification. We monitor the events of
      rebleeding &amp; infection, transfusion amount and hospitalization days We use rebleeding rate
      within 14 days as the primary end point. It is defined as the following events after initial
      stabilization of vital signs for 24 hours; (1): recurrence of hematemesis or bloody stool
      (2); need of transfusion more than 2 unit of blood and systolic pressure &lt; 100 mmHg or pulse
      rate &gt; 100/mn. We use infection rate during admission and mortality rate within 28 days as
      secondary end points.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Patient including &amp; excluding Criteria Including: Those were diagnosed to have
           gastro-esophageal variceal bleeding after endoscopic examination. No evidence suggestive
           of infection was found including: 1)fever more than 37.5。C, 2)leucocytosis with WBC &gt;
           15000 mm3 or immature neutrophils &gt; 500 mm3, 3)PMN of ascites more than
           250/mm3，4)urinalysis, WBC &gt; 15 WBC/HPF, 5)suspected pneuminia in CXR.

           Excluding:1)no consent 2)already has infection 3) antibiotic usage within 14 days 4)
           less than 18 years old 5) pregnancy 6) has malignancy other than HCC 7) allergy to
           ceftriaxone

        2. Management, Allocation and Prophylaxis Those with esophageal variceal bleeding receive
           edoscopic variceal ligation; those with gastric variceal bleeding receive Histoacryl
           injection therapy. They all recieve glypressin 1mg q6h injection for 3 days and start to
           feed on the second day if not contraindicated. We will perform 2nd session of endoscopic
           treatment 14 days later. These patients will randomly alloacted to 2 groups and recieve
           prophylactic antibiotic after 1st endoscopic treatment; Group I: ceftriaxone 500 mg iv
           bolus stat and then q12h for 3 days, Group II: ceftriaxone 500 mg iv bolus stat and then
           q12h for 7 days. If rebleeding occurs after allocation, further treatment was decided by
           attending physician. If active infection occurs during prophylaxis period and no
           improvement was observed for 24 hours, ceftriaxone use will be stopped and further
           treatment was decided by attending physician.

        3. Data record and Surveillance Data Record: We will record the basic data of the patietns:
           including: age, sex, co-morbidity (CAD, heart failure, COPD, chronic liver and renal
           diseases, malignancy, etc);hemogram before allocation,U/A, transfusion amount,ascites
           routine if significant ascites noted,CXR, endoscopic finding of varices; lowest blood
           pressure before allocation, Child-Pugh classification of the patient Surveillance:
           rebleeding and infection during admission, Transfusion amount and hospitalization day
           after allocation, rebleeding rate within 14 days &amp; mortality rate within 28 days.

        4. End points Primary end points: Rebleeding rate within 14 days after initial endoscopic
           treatment. Definition of rebleeding: the following manifestation after stabilization of
           vital sign for 24 hours,(1) appearance of hematemesis and bloody stool(2) need of
           transfusion more than 2 units of blood and vital sign change (systolic pressure &lt; 100
           mmHg or heart rate &gt;100 beats/min).

      Secondary end points: infection during admission, mortality rate within 28 days. Definition
      of infection: 1) bacteremia：positive blood culture, but no definite focus indentified, 2)
      spontaneous bacterial peritonitis : ascites routine: PMN&gt; 250/mm3, 3)urinary tract infection:
      U/A WBC &gt; 15/HPF and positive urine culture, 4)other infections: suspected by clinical,
      radiological or other bacterialogical examination, 5)respiratory tract infection:CXR changes
      with clinical evidence, 6)possible infection: fever (&gt;37.5。C more than 6 hours) and
      leucocytosis,WBC &gt; 15000 mm3 ，but with negative blood culture
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2009</start_date>
  <completion_date type="Actual">April 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>rebleeding rate within 14 days</measure>
    <time_frame>14 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>motarlity rate within 28 days</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">79</enrollment>
  <condition>Esophageal and Gastric Varices</condition>
  <condition>Gastrointestinal Hemorrhage</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ceftrioxone 500mg q12h for 3 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ceftrioxone 500 mg q12h for 7 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ceftrioxone</intervention_name>
    <description>500 mg iv q12h for 3 days</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Rocephin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ceftrioxone</intervention_name>
    <description>500 mg q12h for 7 days</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Rocephin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  those patients suffering from variceal bleeding documented by endoscopic examination
             and without apparent evidence of infection.

        Exclusion Criteria:

          -  received antibiotics within 2 weeks, less than 18 years old, get pregnant, have
             malignancy other than HCC, have allergy to ceftrioxone
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tzong-Hsi Lee, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Far Eastern Memorial Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Far Eastern Memorial Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>22050</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <reference>
    <citation>Bleichner G, Boulanger R, Squara P, Sollet JP, Parent A. Frequency of infections in cirrhotic patients presenting with acute gastrointestinal haemorrhage. Br J Surg. 1986 Sep;73(9):724-6.</citation>
    <PMID>3489499</PMID>
  </reference>
  <reference>
    <citation>Bernard B, Cadranel JF, Valla D, Escolano S, Jarlier V, Opolon P. Prognostic significance of bacterial infection in bleeding cirrhotic patients: a prospective study. Gastroenterology. 1995 Jun;108(6):1828-34.</citation>
    <PMID>7768389</PMID>
  </reference>
  <reference>
    <citation>Bernard B, Grangé JD, Khac EN, Amiot X, Opolon P, Poynard T. Antibiotic prophylaxis for the prevention of bacterial infections in cirrhotic patients with gastrointestinal bleeding: a meta-analysis. Hepatology. 1999 Jun;29(6):1655-61.</citation>
    <PMID>10347104</PMID>
  </reference>
  <reference>
    <citation>Fernández J, Navasa M, Gómez J, Colmenero J, Vila J, Arroyo V, Rodés J. Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis. Hepatology. 2002 Jan;35(1):140-8.</citation>
    <PMID>11786970</PMID>
  </reference>
  <reference>
    <citation>Garcia-Tsao G, Sanyal AJ, Grace ND, Carey WD; Practice Guidelines Committee of American Association for Study of Liver Diseases; Practice Parameters Committee of American College of Gastroenterology. Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. Am J Gastroenterol. 2007 Sep;102(9):2086-102. Erratum in: Am J Gastroenterol. 2007 Dec;102(12):2868.</citation>
    <PMID>17727436</PMID>
  </reference>
  <reference>
    <citation>Husová L, Lata J, Husa P, Senkyrík M, Juránková J, Díte P. Bacterial infection and acute bleeding from upper gastrointestinal tract in patients with liver cirrhosis. Hepatogastroenterology. 2005 Sep-Oct;52(65):1488-90.</citation>
    <PMID>16201103</PMID>
  </reference>
  <reference>
    <citation>Hou MC, Lin HC, Liu TT, Kuo BI, Lee FY, Chang FY, Lee SD. Antibiotic prophylaxis after endoscopic therapy prevents rebleeding in acute variceal hemorrhage: a randomized trial. Hepatology. 2004 Mar;39(3):746-53.</citation>
    <PMID>14999693</PMID>
  </reference>
  <reference>
    <citation>Alonso MJ, Aller MA, Corcuera MT, Nava MP, Gömez F, Angulo A, Arias J. Progressive hepatocytic fatty infiltration in rats with prehepatic portal hypertension. Hepatogastroenterology. 2005 Mar-Apr;52(62):541-6.</citation>
    <PMID>15816474</PMID>
  </reference>
  <reference>
    <citation>Jun CH, Park CH, Lee WS, Joo YE, Kim HS, Choi SK, Rew JS, Kim SJ, Kim YD. Antibiotic prophylaxis using third generation cephalosporins can reduce the risk of early rebleeding in the first acute gastroesophageal variceal hemorrhage: a prospective randomized study. J Korean Med Sci. 2006 Oct;21(5):883-90.</citation>
    <PMID>17043424</PMID>
  </reference>
  <reference>
    <citation>Soriano G, Guarner C, Tomás A, Villanueva C, Torras X, González D, Sainz S, Anguera A, Cussó X, Balanzó J, et al. Norfloxacin prevents bacterial infection in cirrhotics with gastrointestinal hemorrhage. Gastroenterology. 1992 Oct;103(4):1267-72.</citation>
    <PMID>1397884</PMID>
  </reference>
  <reference>
    <citation>Wilbur K, Sidhu K. Antimicrobial therapy in patients with acute variceal hemorrhage. Can J Gastroenterol. 2005 Oct;19(10):607-11.</citation>
    <PMID>16247523</PMID>
  </reference>
  <reference>
    <citation>Pohl J, Pollmann K, Sauer P, Ring A, Stremmel W, Schlenker T. Antibiotic prophylaxis after variceal hemorrhage reduces incidence of early rebleeding. Hepatogastroenterology. 2004 Mar-Apr;51(56):541-6.</citation>
    <PMID>15086198</PMID>
  </reference>
  <reference>
    <citation>Garcia-Tsao G, Sanyal AJ, Grace ND, Carey W; Practice Guidelines Committee of the American Association for the Study of Liver Diseases; Practice Parameters Committee of the American College of Gastroenterology. Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. Hepatology. 2007 Sep;46(3):922-38. Erratum in: Hepatology. 2007 Dec;46(6):2052.</citation>
    <PMID>17879356</PMID>
  </reference>
  <reference>
    <citation>de Franchis R. Evolving consensus in portal hypertension. Report of the Baveno IV consensus workshop on methodology of diagnosis and therapy in portal hypertension. J Hepatol. 2005 Jul;43(1):167-76. Erratum in: J Hepatol. 2005 Sep;43(3):547.</citation>
    <PMID>15925423</PMID>
  </reference>
  <reference>
    <citation>Lata J, Juránková J, Husová L, Senkyrík M, Díte P, Dastych M, Príbramská V, Kroupa R. Variceal bleeding in portal hypertension: bacterial infection and comparison of efficacy of intravenous and per-oral application of antibiotics--a randomized trial. Eur J Gastroenterol Hepatol. 2005 Oct;17(10):1105-10.</citation>
    <PMID>16148557</PMID>
  </reference>
  <reference>
    <citation>Fernández J, Ruiz del Arbol L, Gómez C, Durandez R, Serradilla R, Guarner C, Planas R, Arroyo V, Navasa M. Norfloxacin vs ceftriaxone in the prophylaxis of infections in patients with advanced cirrhosis and hemorrhage. Gastroenterology. 2006 Oct;131(4):1049-56; quiz 1285.</citation>
    <PMID>17030175</PMID>
  </reference>
  <verification_date>January 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 6, 2009</study_first_submitted>
  <study_first_submitted_qc>February 6, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 9, 2009</study_first_posted>
  <last_update_submitted>August 28, 2015</last_update_submitted>
  <last_update_submitted_qc>August 28, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 31, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Far Eastern Memorial Hospital</investigator_affiliation>
    <investigator_full_name>Tzong-Hsi Lee</investigator_full_name>
    <investigator_title>M.D.</investigator_title>
  </responsible_party>
  <keyword>variceal bleeding</keyword>
  <keyword>antibiotic prophylaxis</keyword>
  <keyword>ceftrioxone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Gastrointestinal Hemorrhage</mesh_term>
    <mesh_term>Esophageal and Gastric Varices</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ceftriaxone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

